Showing 5481-5490 of 5956 results for "".
- Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Wet AMD and DMEhttps://modernod.com/news/aerie-pharmaceuticals-initiates-first-in-human-clinical-trial-of-ar-13503-sustained-release-intravitreal-implant-in-patients-with-wet-amd-and-dme/2476812/Aerie Pharmaceuticals announced the commencement of patient dosing in a first-in-human clinical trial of AR-13503 Sustained Release (SR) implant in patients with neovascular age-related macular degeneration (AMD) or diabetic macular edema (DME). This multi-arm, 24-week study (AR-13503-CS20
- Trial of Tele-Ophthalmology System at Regional Health Board in Scotland Shows Promising Resultshttps://modernod.com/news/trial-of-tele-ophthalmology-system-at-regional-health-board-in-scotland-shows-promising-results/2476808/Researchers at the University of Strathclyde and NHS Forth Valley in Scotland have developed a tele-ophthalmology system that, according to recent data, has reduced the need for follow-up appointments and waiting times for treatments in over 50% of cases, according to a
- Prevent Blindness Creates New “Diabetes and the Eyes” Educational Resourcehttps://modernod.com/news/prevent-blindness-creates-new-diabetes-and-the-eyes-educational-resource/2476805/To educate consumers on one of the leading causes of vision loss and blindness, Prevent Blindness has created a new resource, the “
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)https://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-1123-in-patients-with-autosomal-dominant-retinitis-pigmentosa-adrp/2476802/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a phase 1/2 trial for QR-1123 in 2019. QR-1123 is a first-in-class investigational oligonucleotide designed to address the underlying
- OcuNexus Therapeutics Making Progress with Inflammasome Inhibition Program in Ophthalmic Diseasehttps://modernod.com/news/ocunexus-therapeutics-making-significant-progress-with-inflammasome-inhibition-program-in-ophthalmic-disease/2479550/OcuNexus Therapeutics announced that it has strengthened its board of directors with the addition of Rajiv Shukla, who has deep experience in the investment and commercial aspects of the pharmaceutical industry. OcuNexus Therapeutics is a clinical stage biotechnology company develop
- FDA Does Not Approve Kala Pharmaceuticals’ NDA for Dry Eye Disease Candidatehttps://modernod.com/news/fda-does-not-approve-kala-pharmaceuticals-nda-for-dry-eye-disease-candidate/2476799/Kala Pharmaceuticals announced that it received a complete response letter (CRL) from the FDA regarding the company’s new drug application (NDA) for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. The FDA indicated that efficacy data from an additional clinica
- Bausch Health CEO: Big Pharma Will Survive US Drug Regulationshttps://modernod.com/news/bausch-health-ceo-big-pharma-will-survive-us-drug-regulations/2476798/Bausch Health Chariman and CEO Joseph C. Papa told CNBC on Wednesday that he isn’t too concerned about the future of the pharmaceutical industry despite pledges from Congress to lower
- Optronics Introduces Microcast Pro Medical Grade Microscope Video Camera Platformhttps://modernod.com/news/optronics-introduces-microcast-pro-medical-grade-microscope-video-camera-platform/2476796/Optronics announced the introduction of the next generation Microcast, the Microcast 4K PRO 3CMOS 2160p Ultra High Definition, and Microcast HD PRO 3CMOS 1080p high definition microscope video cameras for surgical and other technical microscope imaging applications including pathology, research,
- Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMDhttps://modernod.com/news/opthea-meets-primary-endpoint-in-phase-2b-study-of-opt-302-in-wet-amd/2476795/Opthea announced positive phase 2b results demonstrating that OPT-302 combination therapy met the primary endpoint of superiority in mean visual acuity gain at 24 weeks compared to Lucentis monotherapy in treatment-naïve patients with wet age-related macular degeneration (AMD). <
- Rare Complication of Eye Surgery Can Kill in a Minutehttps://modernod.com/news/rare-complication-of-eye-surgery-can-kill-in-a-minute/2476790/Ocular venous air embolism, a very rare complication of vitrectomy, is almost always fatal, yet some retina specialists have not heard of it, according to a Medscape report. The complication can kill in less than a minute, said Rob